AIM ImmunoTech Reports Fourth Quarter and Full Year 2024 Financial Results and Provides Corporate Update
Continued execution across Ampligen® (rintatolimod) clinical development programs in areas with critical unmet needs, especially in the high-value pancreatic cancer space
Expected milestones over the course of the next 18 months provide significant value-driving opportunities, including some trials being partially funded by collaborators AstraZeneca (pancreatic cancer) and Merck (advanced ovarian cancer)
Company to host conference call and webcast on Tuesday, April 1 st at 8:30 AM ET
OCALA, Fla., March 27, 2025 (GLOBE NEWSWIRE) -- AIM ImmunoTech Inc. (NYSE American: AIM) ('AIM' or the 'Company') today reported its financial results for the fourth quarter and full year 2024 and provided a business update. The Company will host a conference call and webcast on Tuesday, April 1, 2025 at 8:30 AM ET (details below).
'Our team made significant strides in advancing our development programs along with our collaborators over the course of 2024. As we look ahead, we will continue to execute our corporate and clinical strategies to further establish the foundation upon which we can secure the successful future of AIM and our drug Ampligen for the treatment of major-market unmet medical needs. We are focused on the successful execution of a number of key milestones expected over the course of the next 18 months with the goal of building long-term stockholder value,' commented AIM Chief Executive Officer Thomas K. Equels.
Recent Highlights
Announced plans to conduct clinical study of the combination of Ampligen and AstraZeneca's FluMist as an intranasal vaccine for influenza, including avian influenza (bird flu); Paul Goepfert, MD, of the University of Alabama-Birmingham, has agreed to act as the Principal Investigator for the study.
Announced Ted D. Kellner and David Chemerow as new members of AIM's Board of Directors.
Erasmus Medical Center Safety Committee granted approval to proceed with the Phase 2 portion of the Phase 1b/2 clinical trial involving AIM's Ampligen and AstraZeneca's anti-PD-L1 immune checkpoint inhibitor Imfinzi® (durvalumab) in the treatment of late-stage pancreatic cancer ('DURIPANC').
Commenced dosing in Phase 2 of the Phase 1b/2 DURIPANC clinical trial for treatment of late-stage pancreatic cancer.
Announced the final clinical study results for the 'Study to Evaluate the Efficacy and Safety of Ampligen in Patients With Post-COVID Conditions' ('AMP-518') were published to ClinicalTrials.gov (See: NCT05592418).
Expanded patent portfolio with a U.S. compositions and methods patent for Ampligen for the treatment of endometriosis and a Netherlands compositions and methods patent covering Ampligen for use in the Post-COVID condition of fatigue.
Announced publication of data from Roswell Park Comprehensive Cancer Center's Phase 1 study evaluating a combination therapy using Ampligen in early-stage triple-negative breast cancer (TNBC) in The Journal for ImmunoTherapy of Cancer.
Expected Upcoming, Value-Driving Milestones
Metastatic Pancreatic Ductal Adenocarcinoma
Phase 1b/2 Combining Anti-PD-L1 Immune Checkpoint Inhibitor Durvalumab with TLR-3 Agonist Ampligen in Patients with Metastatic Pancreatic Ductal Adenocarcinoma for Therapy Efficacy (DURIPANC) ( NCT05927142); Funded through collaboration of AstraZeneca and Erasmus Medical Center
Q2/Q3 2026: Last patient enrolled in Phase 2
Refractory Melanoma
Phase 2 Polarized Dendritic Cell (aDC1) Based Treatment, Interferon Alpha-2, Ampligen, and Celecoxib for the Treatment of HLA-A2+ Refractory Melanoma ( NCT04093323); Grant funded by National Cancer Institute
H1 2025: First patient dosed
Stage 4 Triple Negative Breast Cancer
Phase 1/2a Study of Ampligen, Celecoxib and Interferon Alpha 2b with Pembrolizumab for the Treatment of Patients with Metastatic or Unresectable Triple Negative Breast Cancer ( NCT05756166); Grant funded by Merck and National Cancer Institute
Q2 2026: Expected completion of enrollment
Advanced Recurrent Ovarian Cancer
Phase 2 Systemic Immune Checkpoint Blockade and Intraperitoneal Chemo-Immunotherapy in Recurrent Ovarian Cancer ( NCT03734692); Grant funded by Merck
H1 2025: Completion of study, publication of data
Summary of Financial Highlights for Fiscal Year 2024
As of December 31, 2024, AIM reported cash, cash equivalents and marketable investments of $4.0 million, compared to $13.1 million as of December 31, 2023.
Research and development expenses for the year ended December 31, 2024, were $6.2 million, compared to $10.9 million for the year ended December 31, 2023.
General and administrative expenses for the year ended December 31, 2024, were $13.7 million, compared to $21.1 million for the year ended December 31, 2023.
Please refer to the full 10-K for complete details.
Conference Call and Webcast Details
The Company will host a conference call and webcast to discuss the Company's Q4/FY2024 operational and financial results on Tuesday, April 1, 2025 at 8:30 AM ET.
The call will be hosted by Thomas K. Equels, Chief Executive Officer of AIM. Interested participants and investors may access the conference call by dialing (877) 407-9219 (domestic) or (201) 689-8852 (international) and referencing the AIM ImmunoTech Conference Call. The webcast will be accessible on the Events page of the Investors section of the Company's website, aimimmuno.com, and will be archived for 90 days following the live event.
About AIM ImmunoTech Inc.
AIM ImmunoTech Inc. is an immuno-pharma company focused on the research and development of therapeutics to treat multiple types of cancers, immune disorders and viral diseases, including COVID-19. The Company's lead product is a first-in-class investigational drug called Ampligen® (rintatolimod), a dsRNA and highly selective TLR3 agonist immuno-modulator with broad spectrum activity in clinical trials for globally important cancers, viral diseases and disorders of the immune system.
For more information, please visit aimimmuno.com and connect with the Company on X, LinkedIn, and Facebook.
Cautionary Statement
This press release contains forward-looking statements within the meaning of the Private Securities Litigation Reform Act of 1995 (the 'PSLRA'). Words such as 'may,' 'will,' 'expect,' 'plan,' 'anticipate,' 'continue,' 'believe,' 'potential,' 'upcoming' and other variations thereon and similar expressions (as well as other words or expressions referencing future events or circumstances) are intended to identify forward-looking statements. Many of these forward-looking statements involve a number of risks and uncertainties. Data, pre-clinical success and clinical success seen to date do not guarantee that Ampligen will be approved as a prophylactic or therapy for any indication. The Company urges investors to consider specifically the various risk factors identified in its most recent Form 10-K, and any risk factors or cautionary statements included in any subsequent Form 10-Q or Form 8-K, filed with the U.S. Securities and Exchange Commission. You are cautioned not to place undue reliance on these forward-looking statements, which speak only as of the date of this press release. Among other things, for those statements, the Company claims the protection of the safe harbor for forward-looking statements contained in the PSLRA. The Company does not undertake to update any of these forward-looking statements to reflect events or circumstances that occur after the date hereof.
Hashtags
Try Our AI Features
Explore what Daily8 AI can do for you:
Comments
No comments yet...
Related Articles
Yahoo
22 minutes ago
- Yahoo
With Lloyds shares red hot, investors should consider this AIM alternative
As Lloyds (LSE:LLOY) shares edges closer to what many investors would consider fair value, my attention is turning to alternative options in the UK banking sector. One AIM-listed name that stands out is Arbuthnot Banking Group (LSE:ARBB). It's much smaller, with a markedly different profile, but appears to be an attractive proposition. And while Lloyds remains a staple for income and stability, Arbuthnot offers a blend of value, growth, and yield. This could appeal to investors seeking something beyond the big high street banks. Looking at the numbers, the contrast between the two banks is striking. In 2025, Arbuthnot is forecast to deliver earnings per share (EPS) of 129.6p. At a share price of around 950p, this equates to a price-to-earnings (P/E) ratio of 7.3. This is a notable discount to Lloyds. The larger bank is expected to post EPS of 6.5p and trades on a forward P/E of 11.8 for the same year. Moving to 2026, Arbuthnot's EPS is forecast to rise to 152.2p. This brings the P/E down to just 6.2. Meanwhile, Lloyds' EPS is expected to reach 9.1p, reducing its P/E to 8.4. By 2027, Arbuthnot's P/E is projected to fall to 5.5, compared to Lloyds at 7. Arbuthnot also wins on the dividend yield. The bank's dividend per share is forecast at 53p in 2025, rising to 57p in 2026 and 61p in 2027. That translates to a yield of 5.6% in 2025, moving up to 6% in 2026 and 6.4% in 2027. Lloyds, by comparison, is expected to pay out 3.4p per share in 2025, 4p in 2026, and 4.6p in 2027, for yields of 4.5%, 5.4%, and 6%, respectively. While Lloyds' income is well covered by earnings, Arbuthnot's payout ratios are similarly conservative. The latter's dividend cover is expected to remain above 1.9 times through the forecast period. Moreover, Arbuthnot trades at a price-to-book ratio of just 0.54 in 2024, well below Lloyds at 0.75, and both are below the sector average, suggesting value in the shares. Arbuthnot's revenue is expected to climb from £179.5m in 2024 to £182.6m in 2025, £193.7m in 2026, and £209.7m in 2027. Lloyds, meanwhile, is forecast to grow revenue from £18.4bn in 2024 to £19.4bn in 2025, and £22.1bn by 2027. In other words, I think we're looking at a similar growth story but just a very different size. While the absolute numbers are not comparable, Arbuthnot's growth rate is strong, and it continues to grow its loan book and deposit base at a healthy clip. Recent results show deposits rising 17% year on year, with a stable loan book and a loan-to-deposit ratio of just 57%. By comparison, Lloyds's is over 90%. However, Arbuthnot's size may heighten risks. It operates in a more specialised, relationship-driven niche and the economic outlook is uncertain, with the UK economy dragging and regulatory changes on the horizon. Nonetheless, this stock certainly interests me. Investors may want to consider this alternative. The post With Lloyds shares red hot, investors should consider this AIM alternative appeared first on The Motley Fool UK. More reading 5 Stocks For Trying To Build Wealth After 50 One Top Growth Stock from the Motley Fool James Fox has positions in Lloyds Banking Group Plc. The Motley Fool UK has recommended Lloyds Banking Group Plc. Views expressed on the companies mentioned in this article are those of the writer and therefore may differ from the official recommendations we make in our subscription services such as Share Advisor, Hidden Winners and Pro. Here at The Motley Fool we believe that considering a diverse range of insights makes us better investors. Motley Fool UK 2025
Yahoo
18 hours ago
- Yahoo
Sturm Ruger CEO sees 2025 bottom line impacted by price repositioning moves
On June 13, Sturm, Ruger & Company provided a communication from Todd Seyfert, CEO, to its employees regarding his first 100 days and management's ongoing corporate strategy initiatives, the company disclosed in a regulatory filing. In the letter to employees, Seyfert stated in part: 'The last few months have been nothing short of transformative – and it's thanks to your focus, dedication, and belief in what we're building. As I have been doing since my first days as CEO, I wanted to update you all transparently and clearly about where I see our short-term and long-term future… With these bold moves, there comes a cost – both emotionally and financially. Change of this scale requires tough decisions, meaningful investment, and short-term impacts that we've chosen to take head-on to position Ruger for long-term strength… It is important to note that we are making these strategic decisions now – thoughtfully and intentionally – so that Ruger is positioned for consistency, stability, and profitable growth in 2026 and beyond. Yet, there will be a cost to the Company for 2025. We expect the expense-related to these initiatives to total approximately $15 million to $20 million over the remainder of the year. We additionally anticipate our price repositioning moves to impact our overall bottom line over that same period. Consequently, we currently believe that our results for the remainder of the year, before the one-time costs and expenses, will look more like prior periods, such as the latter part of 2019, where the Company continued to focus on executing its long-term strategy and delivering long-term value for shareholders in the face of broader industry challenges. These actions will be largely completed by the beginning of 2026, placing Ruger in a strong position for renewed growth and performance in the years to come. Importantly, none of this will slow our momentum when it comes to investing in what matters most, including aggressive new product development and expansion of capacity in areas where market demand exceeds our current ability to supply. We remain fully committed to profitable expansion, product innovation, agile responsiveness, and ensuring we meet the expectations of our customers and the marketplace.' Easily unpack a company's performance with TipRanks' new KPI Data for smart investment decisions Receive undervalued, market resilient stocks right to your inbox with TipRanks' Smart Value Newsletter Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news. Try Now>> See the top stocks recommended by analysts >> Read More on RGR: Disclaimer & DisclosureReport an Issue Sturm Ruger Announces Strategic Initiatives Under New CEO Supreme Court blocks Mexico suit against gunmakers Sturm Ruger Appoints New General Counsel Sturm Ruger Amends By-Laws for Shareholder Actions Sturm Ruger Reports Stable Q1 2025 Financial Results Error in retrieving data Sign in to access your portfolio Error in retrieving data Error in retrieving data Error in retrieving data Error in retrieving data
Yahoo
18 hours ago
- Yahoo
Chanson International prices 16M units at 50c in public offering
Chanson International (CHSN) has priced a best-efforts public offering with gross proceeds to the Company expected to be approximately $8M, before deducting placement agent fees and other estimated expenses payable by the Company, excluding the exercise of any warrant offered. The offering is comprised of 16,000,000 units, consisting of one Class A ordinary share of the Company, par value $0.001 per share, or in lieu thereof, a pre-funded warrant, one series A warrant to purchase one Class A Ordinary Share and one series B warrant to purchase one Class A Ordinary Share. The public offering price of the Units is $0.50 per Unit. Each of the Series A Warrants and the Series B Warrants will have an exercise price of $0.525 per Class A Ordinary Share and be exercisable beginning on the date of the issuance date and ending on the two and half anniversary of the issuance date. The offering is expected to close on or about June 16, 2025, subject to satisfaction of customary closing conditions. The Company intends to use the net proceeds from this offering to open new stores in China and in the U.S., and the specific allocation of net proceeds to each market will be based on market conditions. Univest Securities is acting as sole placement agent for the offering. Easily unpack a company's performance with TipRanks' new KPI Data for smart investment decisions Receive undervalued, market resilient stocks right to your inbox with TipRanks' Smart Value Newsletter Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news. Try Now>> See today's best-performing stocks on TipRanks >> Read More on CHSN: Disclaimer & DisclosureReport an Issue Chanson International files to sell 25M units on 'best-efforts basis' Chanson International Innovates with New Natural Sweetener Blend Chanson International announces self-developed 'Songkang Meal' series Chanson reports on diversity initiatives, responsible business practices Chanson International announces new formulation for sugar Erreur lors de la récupération des données Connectez-vous pour accéder à votre portefeuille Erreur lors de la récupération des données Erreur lors de la récupération des données Erreur lors de la récupération des données Erreur lors de la récupération des données
